...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines.
【24h】

Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines.

机译：Seliciclib（CYC202; r-roscovitine）与人子宫肉瘤细胞系中的细胞毒剂合用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Inhibition of cyclin-dependent kinases (CDKs) has recently emerged as an interesting approach to treat human malignancies. This was explored in human leiomyosarcoma (LMS) lines, which represent a tumour associated with poor survival, chemo-unresponsiveness and deregulation of cell cycle components. MATERIALS AND METHODS: Using isobologram analysis with MTT chemosensitivity testing, the effects of the CDK inhibitor seliciclib (CYC202, R-roscovitine) when used alone or in combination with paclitaxel was studied in uterine cancer cell lines. Apoptotic endpoints were also examined via Annexin V assay using flow cytometry and Western blotting. RESULTS: Overall seliciclib combined with paclitaxel proved synergistic for all cell lines. This was concomitant with an enhanced apoptotic effect and downregulation of the LAP survivin. CONCLUSION: Our data support the use of seliciclib as part of combination therapy for uterine cancer.
机译：背景：细胞周期蛋白依赖性激酶（CDKs）的抑制最近已成为一种有趣的治疗人类恶性肿瘤的方法。在人类平滑肌肉瘤（LMS）系中进行了探索，该系代表与不良生存，化学无反应性和细胞周期成分失控有关的肿瘤。材料与方法：采用等效线图分析和MTT化学敏感性测试，研究了CDK抑制剂seliciclib（CYC202，R-roscovitine）单独使用或与紫杉醇联合使用在子宫癌细胞系中的作用。还通过使用流式细胞术和蛋白质印迹的膜联蛋白V测定法检查了凋亡终点。结果：总体seliciclib与紫杉醇联合使用对所有细胞系均具有协同作用。这与增强的细胞凋亡作用和LAP survivin的下调同时发生。结论：我们的数据支持seliciclib作为子宫癌联合治疗的一部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号